John ten Bosch, Senior Vice President of US-based molecular diagnostics firm BillionToOne, has sold $533,330 (£411,000) worth of company stock, according to a recent filing with the US Securities and Exchange Commission. The transaction, which took place on 13 July 2026, involved the sale of shares at a price not disclosed in the public filing.
The sale comes at a time when the global biotech sector has experienced notable fluctuations, with the Nasdaq Biotechnology Index down roughly 8% since the start of the year. BillionToOne, a privately held company headquartered in California, specialises in non-invasive prenatal testing and liquid biopsy technology. It has raised significant venture capital funding in recent years, including a $125m Series D round in 2024.
Insider stock sales can sometimes signal a lack of confidence in a company's near-term prospects, though they may also reflect personal financial planning. No official reason for the sale was provided in the filing. BillionToOne has not issued a public statement regarding the transaction.
For UK investors with exposure to US biotech through pension funds or ETFs, the sale adds to a cautious mood in the sector. The FTSE All-Share index has been relatively flat this week, but biotech-heavy funds have underperformed amid rising interest rates and tighter capital markets. Analysts at Jefferies noted that private biotech valuations remain under pressure as IPO windows remain narrow.
The broader context includes ongoing regulatory scrutiny of genetic testing markets in both the US and Europe. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has recently updated guidance on direct-to-consumer genetic tests, which could affect companies like BillionToOne if they expand into the UK market.